Literature DB >> 15220362

Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma.

M R Morris1, E Maina, N V Morgan, D Gentle, D Astuti, H Moch, T Kishida, M Yao, P Schraml, F M Richards, F Latif, E R Maher.   

Abstract

BACKGROUND: Overexpression of the hypoxia inducible factor 1 (HIF-1) and HIF-2 transcription factors and the consequent upregulation of hypoxia inducible mRNAs is a feature of many human cancers and may be unrelated to tissue hypoxia. Thus, the VHL (von Hippel-Lindau) tumour suppressor gene (TSG) regulates HIF-1 and HIF-2 expression in normoxia by targeting the alpha subunits for ubiquitination and proteolysis. Inactivation of the VHL TSG in VHL tumours and in sporadic clear cell renal cell carcinoma (RCC) results in overexpression of HIF-1 and HIF-2. However, RCC without VHL inactivation may demonstrate HIF upregulation, suggesting that VHL independent pathways for HIF activation also exist. In RCC, three candidate HIF activating genes exist-FIH-1 (factor inhibiting HIF), SDHB, and FH-which may be dependent or independent of VHL inactivation. AIMS: To investigate FIH-1, SDHB, and FH for somatic mutations in sporadic RCC.
METHODS: Gene mutation was analysed in primary RCCs (clear cell RCCs, papillary RCCs, and oncocytomas) and RCC cell lines. SDHB mutation analysis was performed by denaturing high performance liquid chromatography followed by direct sequencing of aberrant PCR products. FH and FIH-1 mutation analysis were performed by single stranded conformational polymorphism and direct sequencing of PCR products.
RESULTS: No mutations were identified in the three genes investigated.
CONCLUSIONS: There was no evidence to suggest that somatic mutations occur in the FH, FIH-1, or SDHB TSGs in sporadic RCCs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15220362      PMCID: PMC1770369          DOI: 10.1136/jcp.2003.011767

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  32 in total

1.  FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity.

Authors:  P C Mahon; K Hirota; G L Semenza
Journal:  Genes Dev       Date:  2001-10-15       Impact factor: 11.361

2.  Germline SDHD mutation in familial phaeochromocytoma.

Authors:  D Astuti; F Douglas; T W Lennard; I A Aligianis; E R Woodward; D G Evans; C Eng; F Latif; E R Maher
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

3.  Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.

Authors:  M E Cockman; N Masson; D R Mole; P Jaakkola; G W Chang; S C Clifford; E R Maher; C W Pugh; P J Ratcliffe; P H Maxwell
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

4.  Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma.

Authors:  O Gimm; M Armanios; H Dziema; H P Neumann; C Eng
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

5.  Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.

Authors:  M Ohh; C W Park; M Ivan; M A Hoffman; T Y Kim; L E Huang; N Pavletich; V Chau; W G Kaelin
Journal:  Nat Cell Biol       Date:  2000-07       Impact factor: 28.824

6.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma.

Authors:  D Astuti; F Latif; A Dallol; P L Dahia; F Douglas; E George; F Sköldberg; E S Husebye; C Eng; E R Maher
Journal:  Am J Hum Genet       Date:  2001-06-12       Impact factor: 11.025

7.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

8.  The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.

Authors:  S C Clifford; D Astuti; L Hooper; P H Maxwell; P J Ratcliffe; E R Maher
Journal:  Oncogene       Date:  2001-08-16       Impact factor: 9.867

9.  Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.

Authors:  T Kamura; S Sato; K Iwai; M Czyzyk-Krzeska; R C Conaway; J W Conaway
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

10.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.

Authors:  H Zhong; A M De Marzo; E Laughner; M Lim; D A Hilton; D Zagzag; P Buechler; W B Isaacs; G L Semenza; J W Simons
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

View more
  21 in total

Review 1.  Renal cancer: oxygen meets metabolism.

Authors:  Volker H Haase
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

Review 2.  The epigenetic landscape of renal cancer.

Authors:  Mark R Morris; Farida Latif
Journal:  Nat Rev Nephrol       Date:  2016-11-28       Impact factor: 28.314

Review 3.  Hereditary kidney cancer syndromes.

Authors:  Naomi B Haas; Katherine L Nathanson
Journal:  Adv Chronic Kidney Dis       Date:  2014-01       Impact factor: 3.620

Review 4.  [Renal cancer biomarkers. What is justified?].

Authors:  H Moch
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

Review 5.  State of the science: an update on renal cell carcinoma.

Authors:  Eric Jonasch; P Andrew Futreal; Ian J Davis; Sean T Bailey; William Y Kim; James Brugarolas; Amato J Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; Amado J Zurita; Brian I Rini; Pam Sharma; Michael B Atkins; Cheryl L Walker; W Kimryn Rathmell
Journal:  Mol Cancer Res       Date:  2012-05-25       Impact factor: 5.852

6.  Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC.

Authors:  Toshinari Yamasaki; Tram Anh T Tran; Orhan K Oz; Ganesh V Raj; Roderich E Schwarz; Ralph J Deberardinis; Xuewu Zhang; James Brugarolas
Journal:  Nat Rev Urol       Date:  2011-02-08       Impact factor: 14.432

7.  Factor inhibiting HIF1α (FIH-1) functions as a tumor suppressor in human colorectal cancer by repressing HIF1α pathway.

Authors:  Tao Chen; Zhong Ren; Le-Chi Ye; Ping-Hong Zhou; Jian-Min Xu; Qiang Shi; Li-Qing Yao; Yun-Shi Zhong
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 8.  Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy.

Authors:  Elizabeth Cartwright Pfaffenroth; W Marston Linehan
Journal:  Expert Opin Biol Ther       Date:  2008-06       Impact factor: 4.388

9.  Protein kinase C-mediated modulation of FIH-1 expression by the homeodomain protein CDP/Cut/Cux.

Authors:  Jinping Li; Enfeng Wang; Shamit Dutta; Julie S Lau; Shi-wen Jiang; Kaustubh Datta; Debabrata Mukhopadhyay
Journal:  Mol Cell Biol       Date:  2007-08-06       Impact factor: 4.272

Review 10.  SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes.

Authors:  B Pasini; C A Stratakis
Journal:  J Intern Med       Date:  2009-07       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.